AFMD Overview
Upcoming Projects (AFMD)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (AFMD)
-
A Second View: Delving into Affimed's innate cell engager AFM13 for treating CD30-positive lymphoma
Ticker: AFMD
Executed On: Jan 25, 2023 at 04:00 PM EST -
A second view: Digging into the Phase 1 data on Affimed's AFM24 and atezolizumab combination in patients with EGFR+ solid tumors
Ticker: AFMD
Executed On: Jan 24, 2023 at 09:00 AM EST -
Digging into the Phase 1 data on Affimed's AFM24 and atezolizumab combination in patients with EGFR+ solid tumors
Ticker: AFMD
Executed On: Jan 10, 2023 at 10:30 AM EST -
Delving into the recent data from ASH2022 on Affimed's innate cell engager AFM13 for treating CD30-positive lymphoma
Ticker: AFMD
Executed On: Dec 22, 2022 at 11:30 AM EST -
Digging in to the Affimed IV data on AFM13 in Lymphoma presented at AACR
Ticker: AFMD
Executed On: Apr 14, 2022 at 10:00 AM EDT
Expired Projects (AFMD)
-
Unveiling the Potential of AFM24 in EGFR-Wildtype Non-Small Cell Lung Cancer: Insights from the AFM24-102 Phase 1/2a Study
Ticker: AFMD
Execute By: Feb 29, 2024 -
Unveiling the Promise of AFM13 in Advanced-Stage r/r PTCL: A Dive into the Phase 1/2 Study Results at ASH 2023
Ticker: AFMD
Execute By: Jan 31, 2024 -
Discussing Affimed’s AFM24 recent results in patients with solid tumors.
Ticker: AFMD
Execute By: Dec 31, 2022
Upcoming & Overdue Catalysts (AFMD)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (AFMD)
-
Affimed (AFMD) Places AFM11 (CD19/CD3-Targeting T cell Engager) Phase 1 Program on Clinical Hold
Ticker: AFMD
Occurred on: Oct 08, 2018 -
Affimed (AFMD) Reports New Data for AFM13 from Two Separate Clinical Trials in Hodgkin and CD30-Positive Lymphomas
Ticker: AFMD
Occurred on: Feb 01, 2018 -
AFM13 Phase 2a interim data due 2Q 2016 in Hodgkin lymphoma (HL) for Affimed’s lead candidate
Ticker: AFMD
Occurred on: Dec 06, 2016 -
Affimed (AFMD) Presents Preclinical Data on Lead Candidate AFM13 at the Annual Meeting of the Society for Natural Immunity
Ticker: AFMD
Occurred on: Oct 04, 2016 -
Phase 1b study assessing AFM13/KEYTRUDA combo in lymphoma to be initiated in the first half of 2016
Tickers: AFMD, MRK
Occurred on: Aug 10, 2016
Strategic Initiatives (AFMD)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
